Key Takeaways
-
The largest real-world study of dutasteride mesotherapy for hair loss — 541 patients across multiple clinical centres, tracked for a minimum of 6 months, providing invaluable data on how this treatment performs outside the controlled conditions of a clinical trial.
-
38.4% of evaluable monotherapy patients showed marked improvement — among the 86 patients who received dutasteride mesotherapy as their sole treatment and could be assessed after one year, over a third achieved notable clinical improvement.
-
No serious or sexual adverse events — across all 541 patients, not a single case of serious side effects or sexual dysfunction was reported, addressing one of the biggest concerns patients have about DHT-blocking treatments.
-
Pain was the most common side effect — 45.5% of patients reported injection-site pain, but this was described as mild and self-limited, resolving without intervention.
-
Effective in both men and women — the study included patients of both sexes with androgenetic alopecia, confirming that dutasteride mesotherapy can benefit female as well as male pattern hair loss.
Evidence at a Glance
| Evidence Level |
Level 3 — Multicentric retrospective cohort study (real-world evidence) |
| Sample Size |
541 patients across multiple clinical centres |
| Key Result |
38.4% marked improvement in evaluable monotherapy patients (33 of 86) |
| Treatment Protocol |
Quarterly injections of 0.01% dutasteride (1 mL intradermal) |
| Follow-up |
Minimum 6 months; monotherapy assessment at 1 year |
| Safety |
No serious or sexual adverse events in 541 patients |
About This Study
| Authors |
David Saceda-Corralo, Farah Moustafa, Óscar Moreno-Arrones, Pedro Jaén-Olasolo, Sergio Vañó-Galván, Francisco Camacho |
| Journal |
Journal of Drugs in Dermatology (JDD) |
| Year |
2022 (published July) |
| Volume/Pages |
Vol. 21, Issue 7, pp. 742–747 |
| Type |
Multicentric retrospective study |
| PMID |
35816059 |
| DOI |
10.36849/JDD.6610 |
| Full Paper |
View on PubMed → |
Note: This is a plain-language summary of the published research paper. The original study was conducted independently and is not affiliated with Hairgenetix. We present this summary to make scientific research more accessible to people experiencing hair loss.
Reviewed by: Esther Bodde, MSc — Health Scientist and Medical Research Analyst at Hairgenetix. Esther holds a Master of Science degree and specialises in translating clinical research into clear, evidence-based consumer information. This summary was reviewed for scientific accuracy, fair representation of results, and clear communication of study limitations.
Why This Research Matters
Clinical trials are essential for establishing whether a treatment works, but they come with significant limitations: they typically involve carefully selected patients, strictly controlled protocols, and relatively small sample sizes. The real question that patients and clinicians need answered is: does this treatment work in the messier reality of everyday clinical practice?
That's exactly what this study addresses. With 541 patients from multiple dermatology centres, this is the largest published study to examine dutasteride mesotherapy for androgenetic alopecia in real-world clinical conditions. Patients weren't cherry-picked for ideal characteristics. Treatments weren't administered under laboratory conditions. This is mesotherapy as it's actually delivered in clinics — with all the natural variation that entails.
The results provide clinicians and patients with something clinical trials alone cannot: confidence that dutasteride mesotherapy works outside the controlled trial setting, and detailed safety data from a patient population large enough to detect uncommon adverse events. The finding of zero serious or sexual adverse events across 541 patients is particularly reassuring, as sexual side effects are a significant concern with systemic DHT-blocking medications.
What The Researchers Did
Saceda-Corralo and colleagues conducted a multicentre retrospective analysis — meaning they looked back through the medical records of patients who had already received dutasteride mesotherapy as part of their regular clinical care at multiple dermatology centres in Spain.
The study included 541 patients with androgenetic alopecia (both male and female) who had received at least one dutasteride mesotherapy session and had a minimum of 6 months of follow-up data. The treatment protocol consisted of intradermal injections of 0.01% dutasteride (1 mL per session) delivered quarterly — one session every 3 months.
The researchers assessed two main areas:
-
Safety: All adverse events were documented across the full 541-patient cohort, including pain, scarring, infection, systemic effects, and sexual adverse events.
-
Efficacy: Of the 541 patients, 86 (15.9%) had received dutasteride mesotherapy as monotherapy (without other concurrent hair loss treatments) and had completed at least one year of follow-up. These 86 patients formed the evaluable efficacy cohort, as their results could be attributed specifically to the mesotherapy rather than a combination of treatments.
Clinical improvement was assessed using standardised photographic documentation, with responses categorised as marked improvement, moderate improvement, no change, or worsening.
Understanding the Research Methods
What is a retrospective study and how does it differ from a clinical trial? In a clinical trial (prospective study), researchers design the study first and then enrol patients. In a retrospective study, researchers look back at data that was already collected during routine clinical care. This means the data reflects real-world practice but lacks the tight controls of a trial. Retrospective studies are valuable for assessing safety in large populations and understanding how treatments perform in everyday settings.
Why multicentric? Drawing patients from multiple dermatology centres — rather than a single clinic — reduces the risk that results are specific to one practitioner's technique, one patient population, or one clinic's protocols. It provides a broader, more generalisable picture of how the treatment works across different settings.
Why were only 86 of 541 patients assessed for efficacy? Most patients in real-world practice use multiple treatments simultaneously (oral medications, topical minoxidil, PRP, etc.). When a patient improves while using three treatments at once, you can't determine which one is responsible. By focusing the efficacy analysis on the 86 patients who received dutasteride mesotherapy as their only treatment, the researchers could more confidently attribute any improvement to the mesotherapy itself.
Why is the safety data so valuable here? Clinical trials typically include 30-150 patients. Rare adverse events that occur in, say, 1 in 200 patients would likely be missed in a trial of 100. With 541 patients, this study has much greater power to detect uncommon side effects. The absence of serious or sexual adverse events across this large cohort is therefore more meaningful than the same finding in a smaller trial.
What They Found
38.4% showed marked improvement: Of the 86 patients who received dutasteride mesotherapy as monotherapy and were evaluable at one year, 33 patients (38.4%) demonstrated marked clinical improvement on standardised photographs. Most of the remaining patients also showed some degree of improvement, confirming the treatment's effectiveness as a standalone therapy.
Zero serious adverse events: Across all 541 patients in the study — including those receiving combination treatments — not a single serious adverse event was recorded. This includes no cases of scarring, infection, or systemic complications from the intradermal dutasteride delivery.
Zero sexual adverse events: Perhaps the most clinically important safety finding: no sexual side effects were reported in any of the 541 patients. This is significant because oral dutasteride and finasteride carry a well-documented risk of sexual dysfunction, which is one of the primary reasons many patients avoid these medications. Local delivery via mesotherapy appears to avoid this problem.
Pain was common but mild: Injection-site pain was the most frequently reported side effect, affecting 246 patients (45.5%). However, this pain was consistently described as mild and self-limited — resolving on its own without treatment. No other adverse events occurred at significant rates.
Hormones unchanged: Laboratory tests showed no significant differences in serum hormone levels before and after the mesotherapy treatment. This confirms that intradermal delivery of dutasteride at 0.01% concentration does not meaningfully alter systemic hormone levels — explaining why sexual side effects were absent.
Effective for both sexes: The study confirmed effectiveness in both male and female patients with androgenetic alopecia, making this one of the few treatments with evidence of benefit across both populations.
Figure 1: Summary of findings from Saceda-Corralo et al. (2022). Left: clinical improvement rates among 86 evaluable monotherapy patients after one year. Centre: safety profile across all 541 patients. Right: comparison of adverse event rates between mesotherapy delivery and oral administration of dutasteride. Data source: JDD 2022;21(7):742-747.
How Dutasteride Mesotherapy Works
Dutasteride's mechanism: Dutasteride is a dual 5-alpha reductase inhibitor, blocking both Type I and Type II isoforms of the enzyme that converts testosterone into dihydrotestosterone (DHT). DHT is the primary androgen responsible for miniaturising genetically sensitive hair follicles in androgenetic alopecia. By reducing local DHT levels, dutasteride slows or reverses the progressive shrinking of hair follicles.
Why 0.01% concentration via mesotherapy? The concentration used in this study (0.01%) is far lower than the 0.5mg oral dose typically prescribed. The rationale is that direct intradermal delivery places the drug exactly where it's needed — at the hair follicle level — so a much lower total dose can achieve effective local concentrations. This dramatically reduces systemic exposure, which is why this study found no changes in serum hormone levels and no sexual side effects.
The mesotherapy delivery advantage: Intradermal injection bypasses the skin's barrier function entirely, delivering the active ingredient directly to the dermis where hair follicle bulbs reside. Unlike topical application, which relies on passive diffusion through the stratum corneum (and typically achieves only 1-5% penetration), mesotherapy achieves near-100% local delivery of the injected volume. This principle of enhanced local delivery is shared with microneedling, which creates temporary channels for topical absorption.
Quarterly dosing rationale: Dutasteride has a long half-life (approximately 5 weeks), meaning a single dose remains active for an extended period. Combined with the slow-release depot effect of intradermal injection, quarterly sessions (every 3 months) maintain sufficient local drug levels while minimising the total number of treatments needed.
Clinical Interpretation
This study's greatest contribution is not discovering that dutasteride mesotherapy works — earlier smaller trials had already suggested efficacy. Rather, it's confirming that the treatment works safely in real-world clinical practice at scale, and that local delivery avoids the systemic side effects that limit oral dutasteride's use.
Interpreting the 38.4% "marked improvement" rate: This figure refers only to the monotherapy subgroup after one year, not the full 541 patients. It tells us that about 4 in 10 patients who used dutasteride mesotherapy alone — without any other treatments — achieved notable visible improvement. The remaining patients also showed some degree of benefit, with clinical improvement reported in most of the evaluable cohort. In real-world settings (where compliance may vary, protocols may differ between centres, and patients are unselected), a 38.4% marked improvement rate is clinically meaningful.
The safety signal is the headline: For many patients, the decision about hair loss treatment is driven by safety concerns as much as efficacy. The finding that 541 patients experienced zero serious or sexual adverse events — when the oral form of the same drug carries meaningful sexual side effect risks — is the most impactful result for clinical decision-making. It suggests that mesotherapy delivery fundamentally changes the risk-benefit profile of dutasteride.
Unchanged hormone levels explain the safety: The laboratory confirmation that serum hormone levels were unaffected by the treatment provides a mechanistic explanation for the absence of sexual side effects. The drug stays local rather than going systemic — which is the entire therapeutic rationale for mesotherapy delivery.
How This Compares With Other Research
| Study |
Treatment |
Patients |
Key Finding |
| Saceda-Corralo 2022 (this study) |
Dutasteride 0.01% mesotherapy |
541 (real-world) |
38.4% marked improvement; 0 serious AEs |
| Moftah 2013 |
Dutasteride 0.05% mesotherapy |
126 women |
62.8% photographic improvement vs 17.5% control |
| Oral dutasteride trials |
Dutasteride 0.5mg oral |
Various |
Superior efficacy but 4-7% sexual side effect rate |
| Sun 2022 (systematic review) |
Mesotherapy (various agents) |
Review |
Mesotherapy shows promise; evidence quality varies |
The comparison with oral dutasteride is particularly instructive. Oral dutasteride typically achieves somewhat higher efficacy rates due to the higher dose and continuous systemic exposure, but at the cost of meaningful sexual side effect rates (4-7% in published trials). Mesotherapy delivery sacrifices some absolute efficacy for a dramatically improved safety profile — making it especially suitable for patients who are concerned about or have previously experienced sexual side effects from oral DHT blockers.
Treatment Protocol Details
| Active Ingredient |
Dutasteride 0.01% solution |
| Injection Volume |
1 mL per session |
| Delivery Method |
Intradermal mesotherapy injections across the affected scalp area |
| Session Frequency |
Quarterly (once every 3 months) |
| Year One Protocol |
4 sessions (quarters 1–4) |
| Follow-up Period |
Minimum 6 months; efficacy assessed at 1 year |
| Patient Population |
Men and women with androgenetic alopecia |
Important note: Dutasteride mesotherapy is a clinical procedure that must be performed by a qualified dermatologist. The 0.01% concentration used in this study is specifically formulated for intradermal delivery and is not the same as oral dutasteride preparations. Never attempt to self-administer dutasteride injections.
Research Limitations to Consider
-
Retrospective design: Because this study looked back at existing records rather than following patients prospectively, the data quality depends on how consistently each centre documented outcomes. Some data points may be missing or inconsistently recorded across different clinics.
-
No control group: Unlike the Moftah 2013 study, this analysis did not include a placebo or active control group. Without a comparator, we cannot quantify how much of the observed improvement is attributable specifically to dutasteride versus the natural fluctuation of hair loss or the mesotherapy procedure itself.
-
Small evaluable efficacy cohort: Only 86 of 541 patients (15.9%) met the criteria for monotherapy efficacy assessment. The remaining 455 patients were using additional treatments, making it impossible to attribute their results solely to mesotherapy. This small evaluable group limits the precision of the efficacy estimates.
-
Subjective improvement assessment: Clinical improvement was categorised as "marked," "moderate," or "none" based on photographic assessment, without quantitative measures like hair counts or trichoscopy data. This introduces subjectivity into the efficacy assessment.
-
No long-term data beyond one year: The monotherapy efficacy assessment was conducted at one year. Whether results continue to improve, plateau, or decline with continued quarterly sessions is not addressed.
-
Single country: All participating centres were in Spain, which may limit generalisability to different ethnic populations where androgenetic alopecia patterns and treatment responses may differ.
What This Means For Your Hair
This real-world study provides important context for anyone considering their hair loss treatment options. Here's what it means in practical terms:
-
Mesotherapy is a viable delivery method for active ingredients: The core principle demonstrated here — that delivering active ingredients directly into the scalp produces results while minimising systemic side effects — validates the entire approach of enhanced scalp delivery. Whether via clinical mesotherapy injections or at-home microneedling with topical serums, getting ingredients past the skin barrier and closer to the follicle is more effective than surface application alone.
-
Local delivery changes the safety equation: The absence of sexual side effects in 541 patients, when the same drug taken orally carries a 4-7% risk, is a powerful demonstration that how you deliver a treatment matters as much as what you deliver. This principle applies broadly to scalp treatments.
-
Real-world evidence should complement clinical trials: If a treatment only works under perfect laboratory conditions with carefully selected patients, its value is limited. This study shows that dutasteride mesotherapy maintains its benefits when delivered in the variability of everyday clinical practice.
-
At-home microneedling applies the same delivery principle: While mesotherapy requires a clinical setting and prescription medications, at-home microneedling with a derma roller creates similar (though shallower) channels in the scalp that enhance the penetration of topical treatments. The Hairgenetix protocol — combining microneedling with copper peptide serum — leverages this same enhanced-delivery approach in a form you can use at home.
Key Terms Explained
- Retrospective Study
- A research design that analyses data collected in the past, typically from medical records or clinical databases. Unlike prospective studies (where researchers follow patients forward in time), retrospective studies look backward. They are valuable for studying safety in large populations and assessing real-world treatment performance, but provide weaker evidence for causation than randomised controlled trials.
- Multicentric
- A study conducted across multiple clinical sites (hospitals or clinics), rather than a single location. Multicentre studies are more generalisable because they include different practitioners, populations, and practice patterns, reducing the risk that results are specific to one setting.
- Monotherapy
- Using a single treatment alone, without combining it with other therapies. In this study, the 86 monotherapy patients received only dutasteride mesotherapy — no oral medications, topical minoxidil, or other hair loss treatments — allowing their results to be attributed specifically to the mesotherapy.
- Dutasteride
- A medication that inhibits both Type I and Type II 5-alpha reductase enzymes, which convert testosterone into the more potent androgen DHT (dihydrotestosterone). It is more comprehensive than finasteride (which only blocks Type II). Approved for benign prostatic hyperplasia, it is used off-label for androgenetic alopecia.
- Intradermal Injection
- An injection delivered into the dermis — the layer of skin just below the surface epidermis. The dermis is where hair follicle bulbs, blood vessels, and nerve endings reside. Intradermal injection achieves high local drug concentrations while minimising absorption into the bloodstream.
- Serum Hormone Levels
- Measurements of hormones (such as testosterone, DHT, and others) circulating in the blood. Unchanged serum levels after treatment indicate that the drug is not significantly reaching the systemic circulation — confirming that its effects remain localised to the injection site.
- Real-World Evidence (RWE)
- Clinical data collected from routine medical practice rather than controlled clinical trials. RWE complements trial data by showing how treatments perform in the diversity and complexity of everyday healthcare, including patients who would typically be excluded from clinical trials.
- Sexual Adverse Events
- Side effects affecting sexual function, including reduced libido, erectile dysfunction, and ejaculatory disorders. These are known risks of oral 5-alpha reductase inhibitors (finasteride and dutasteride) and are a primary reason many patients discontinue or avoid these medications.
Frequently Asked Questions
Why is 0 sexual side effects in 541 patients such a big deal?
Oral dutasteride (0.5mg daily) carries a sexual side effect rate of approximately 4-7% in clinical trials. These effects — including reduced libido, erectile dysfunction, and ejaculatory changes — are the primary reason many patients refuse or discontinue oral DHT-blocking therapy. Finding zero cases across 541 patients treated with intradermal delivery suggests that mesotherapy fundamentally changes the drug's side effect profile by keeping it local rather than systemic. This is corroborated by the finding that serum hormone levels were unchanged after treatment. For the millions of people reluctant to take oral dutasteride due to side effect concerns, this represents a potentially important alternative delivery route.
Is 38.4% marked improvement a good result?
In context, yes. First, this figure represents "marked" improvement specifically — the highest category. Additional patients showed moderate improvement, meaning the total responder rate was higher than 38.4%. Second, this was assessed in a real-world setting with unselected patients, where results are typically lower than in optimised clinical trials. Third, these were monotherapy patients — the results might be even better when combined with other treatments (as most of the 541 patients were doing). For comparison, topical minoxidil 2% typically achieves visible improvement in 30-40% of women, and this study's monotherapy improvement rate is competitive with that benchmark.
Why did only 86 out of 541 patients get assessed for efficacy?
This is actually good scientific practice, not a limitation. Most patients receiving mesotherapy in real clinical practice also use other treatments — oral medications, topical minoxidil, PRP, etc. If a patient improves while using four treatments simultaneously, you can't determine which one is responsible. By restricting the efficacy analysis to the 86 patients who used mesotherapy as their only treatment, the researchers could be more confident that any improvement was due to the mesotherapy itself. The safety analysis, by contrast, used all 541 patients — because adverse events are attributable regardless of concurrent treatments.
How does dutasteride mesotherapy compare with minoxidil?
These treatments work through completely different mechanisms and are not direct competitors — they're complementary. Dutasteride blocks DHT production, addressing the hormonal driver of follicle miniaturisation. Minoxidil is a vasodilator and potassium channel opener that stimulates hair growth independently of hormonal pathways. Many clinicians use them together for maximum benefit. This study focused on mesotherapy delivery of dutasteride, but the enhanced-delivery principle applies to topical treatments too — which is where microneedling comes in.
Can I get dutasteride mesotherapy at a clinic near me?
Dutasteride mesotherapy is offered by some dermatology clinics and trichology centres, particularly in Europe, the Middle East, and parts of Asia. Availability varies by country and is influenced by local medical regulations. In some jurisdictions, dutasteride mesotherapy is considered an off-label use. When seeking treatment, ask about the specific concentration used (this study used 0.01%), the injection technique, session frequency, and whether the practitioner has experience with this specific protocol. Prices typically range from $200–500 per session, with quarterly sessions recommended.
Does this study prove mesotherapy is better than oral dutasteride?
No — this study didn't directly compare mesotherapy delivery against oral delivery. The oral form likely achieves somewhat higher efficacy rates due to the higher systemic dose, but at the cost of meaningful sexual side effect risks. What this study demonstrates is that mesotherapy provides meaningful clinical improvement with a dramatically better safety profile. Whether the trade-off of slightly lower efficacy for much better safety is worthwhile depends on the individual patient's priorities. For many patients — particularly those who have declined oral therapy due to side effect concerns — mesotherapy offers a middle ground that may not have existed before.
How does mesotherapy delivery relate to at-home microneedling?
Both mesotherapy and microneedling are based on the principle that getting past the skin barrier dramatically improves treatment delivery to hair follicles. Mesotherapy achieves this through professional intradermal injections with active drug solutions. Microneedling creates temporary micro-channels that allow topically applied products to penetrate much more deeply than they would through intact skin. While microneedling doesn't achieve the same depth or precision of drug delivery as mesotherapy, it shares the core principle and is accessible for home use. The Hairgenetix system combines microneedling with copper peptide serum — an evidence-based active ingredient — to leverage this enhanced-delivery mechanism at home.
Why were serum hormone levels unchanged despite using a DHT blocker?
This is the key finding that explains the safety profile. When dutasteride is taken orally at 0.5mg, it reaches the bloodstream and blocks 5-alpha reductase throughout the body, reducing serum DHT by approximately 90%. This systemic effect is responsible for the drug's sexual side effects. In this study, intradermal injection of just 1 mL of 0.01% dutasteride (a total dose of 0.1mg, delivered locally) achieved sufficient concentrations at the hair follicle level while being too dilute to meaningfully affect systemic hormone levels. The drug stayed where it was needed — in the scalp — rather than circulating throughout the body.
Original Study Citation
Saceda-Corralo, D., Moustafa, F., Moreno-Arrones, Ó., Jaén-Olasolo, P., Vañó-Galván, S., & Camacho, F. (2022). Mesotherapy with dutasteride for androgenetic alopecia: A retrospective study in real clinical practice. Journal of Drugs in Dermatology, 21(7), 742–747. https://doi.org/10.36849/JDD.6610
How to Cite This Summary
APA: Hairgenetix. (2025). Mesotherapy for hair loss: Real-world results from 541 patients — Plain-language study summary. Hairgenetix Research Library. https://hairgenetix.com/blogs/articles/mesotherapy-hair-loss-real-world-541-patients-2022
Informal: A 2022 multicentre retrospective study of 541 patients found that dutasteride mesotherapy produced marked improvement in 38.4% of monotherapy patients with zero serious or sexual adverse events (Saceda-Corralo et al., 2022). Summarised by Hairgenetix at hairgenetix.com.
Last reviewed and updated: March 2025 · Based on original publication: July 2022
Enhanced Delivery: The Principle Behind Hairgenetix
This study demonstrates that delivering active ingredients directly to hair follicles — bypassing the skin barrier — produces meaningful results with an excellent safety profile. Whether through clinical mesotherapy injections or at-home microneedling, the principle is the same: enhanced delivery works.
The Hairgenetix system brings this principle home. Our medical-grade derma roller creates micro-channels that dramatically increase the absorption of our copper peptide serum — a scientifically studied active ingredient — directly into the scalp where follicles need it most.
Browse the Hairgenetix Collection →
Mesotherapy for Hair Loss: Real-World Results From 541 Patients (2022)
Key Takeaways
Evidence at a Glance
About This Study
Why This Research Matters
Clinical trials are essential for establishing whether a treatment works, but they come with significant limitations: they typically involve carefully selected patients, strictly controlled protocols, and relatively small sample sizes. The real question that patients and clinicians need answered is: does this treatment work in the messier reality of everyday clinical practice?
That's exactly what this study addresses. With 541 patients from multiple dermatology centres, this is the largest published study to examine dutasteride mesotherapy for androgenetic alopecia in real-world clinical conditions. Patients weren't cherry-picked for ideal characteristics. Treatments weren't administered under laboratory conditions. This is mesotherapy as it's actually delivered in clinics — with all the natural variation that entails.
The results provide clinicians and patients with something clinical trials alone cannot: confidence that dutasteride mesotherapy works outside the controlled trial setting, and detailed safety data from a patient population large enough to detect uncommon adverse events. The finding of zero serious or sexual adverse events across 541 patients is particularly reassuring, as sexual side effects are a significant concern with systemic DHT-blocking medications.
What The Researchers Did
Saceda-Corralo and colleagues conducted a multicentre retrospective analysis — meaning they looked back through the medical records of patients who had already received dutasteride mesotherapy as part of their regular clinical care at multiple dermatology centres in Spain.
The study included 541 patients with androgenetic alopecia (both male and female) who had received at least one dutasteride mesotherapy session and had a minimum of 6 months of follow-up data. The treatment protocol consisted of intradermal injections of 0.01% dutasteride (1 mL per session) delivered quarterly — one session every 3 months.
The researchers assessed two main areas:
Clinical improvement was assessed using standardised photographic documentation, with responses categorised as marked improvement, moderate improvement, no change, or worsening.
Understanding the Research Methods
What is a retrospective study and how does it differ from a clinical trial? In a clinical trial (prospective study), researchers design the study first and then enrol patients. In a retrospective study, researchers look back at data that was already collected during routine clinical care. This means the data reflects real-world practice but lacks the tight controls of a trial. Retrospective studies are valuable for assessing safety in large populations and understanding how treatments perform in everyday settings.
Why multicentric? Drawing patients from multiple dermatology centres — rather than a single clinic — reduces the risk that results are specific to one practitioner's technique, one patient population, or one clinic's protocols. It provides a broader, more generalisable picture of how the treatment works across different settings.
Why were only 86 of 541 patients assessed for efficacy? Most patients in real-world practice use multiple treatments simultaneously (oral medications, topical minoxidil, PRP, etc.). When a patient improves while using three treatments at once, you can't determine which one is responsible. By focusing the efficacy analysis on the 86 patients who received dutasteride mesotherapy as their only treatment, the researchers could more confidently attribute any improvement to the mesotherapy itself.
Why is the safety data so valuable here? Clinical trials typically include 30-150 patients. Rare adverse events that occur in, say, 1 in 200 patients would likely be missed in a trial of 100. With 541 patients, this study has much greater power to detect uncommon side effects. The absence of serious or sexual adverse events across this large cohort is therefore more meaningful than the same finding in a smaller trial.
What They Found
Figure 1: Summary of findings from Saceda-Corralo et al. (2022). Left: clinical improvement rates among 86 evaluable monotherapy patients after one year. Centre: safety profile across all 541 patients. Right: comparison of adverse event rates between mesotherapy delivery and oral administration of dutasteride. Data source: JDD 2022;21(7):742-747.
How Dutasteride Mesotherapy Works
Dutasteride's mechanism: Dutasteride is a dual 5-alpha reductase inhibitor, blocking both Type I and Type II isoforms of the enzyme that converts testosterone into dihydrotestosterone (DHT). DHT is the primary androgen responsible for miniaturising genetically sensitive hair follicles in androgenetic alopecia. By reducing local DHT levels, dutasteride slows or reverses the progressive shrinking of hair follicles.
Why 0.01% concentration via mesotherapy? The concentration used in this study (0.01%) is far lower than the 0.5mg oral dose typically prescribed. The rationale is that direct intradermal delivery places the drug exactly where it's needed — at the hair follicle level — so a much lower total dose can achieve effective local concentrations. This dramatically reduces systemic exposure, which is why this study found no changes in serum hormone levels and no sexual side effects.
The mesotherapy delivery advantage: Intradermal injection bypasses the skin's barrier function entirely, delivering the active ingredient directly to the dermis where hair follicle bulbs reside. Unlike topical application, which relies on passive diffusion through the stratum corneum (and typically achieves only 1-5% penetration), mesotherapy achieves near-100% local delivery of the injected volume. This principle of enhanced local delivery is shared with microneedling, which creates temporary channels for topical absorption.
Quarterly dosing rationale: Dutasteride has a long half-life (approximately 5 weeks), meaning a single dose remains active for an extended period. Combined with the slow-release depot effect of intradermal injection, quarterly sessions (every 3 months) maintain sufficient local drug levels while minimising the total number of treatments needed.
Clinical Interpretation
This study's greatest contribution is not discovering that dutasteride mesotherapy works — earlier smaller trials had already suggested efficacy. Rather, it's confirming that the treatment works safely in real-world clinical practice at scale, and that local delivery avoids the systemic side effects that limit oral dutasteride's use.
Interpreting the 38.4% "marked improvement" rate: This figure refers only to the monotherapy subgroup after one year, not the full 541 patients. It tells us that about 4 in 10 patients who used dutasteride mesotherapy alone — without any other treatments — achieved notable visible improvement. The remaining patients also showed some degree of benefit, with clinical improvement reported in most of the evaluable cohort. In real-world settings (where compliance may vary, protocols may differ between centres, and patients are unselected), a 38.4% marked improvement rate is clinically meaningful.
The safety signal is the headline: For many patients, the decision about hair loss treatment is driven by safety concerns as much as efficacy. The finding that 541 patients experienced zero serious or sexual adverse events — when the oral form of the same drug carries meaningful sexual side effect risks — is the most impactful result for clinical decision-making. It suggests that mesotherapy delivery fundamentally changes the risk-benefit profile of dutasteride.
Unchanged hormone levels explain the safety: The laboratory confirmation that serum hormone levels were unaffected by the treatment provides a mechanistic explanation for the absence of sexual side effects. The drug stays local rather than going systemic — which is the entire therapeutic rationale for mesotherapy delivery.
How This Compares With Other Research
The comparison with oral dutasteride is particularly instructive. Oral dutasteride typically achieves somewhat higher efficacy rates due to the higher dose and continuous systemic exposure, but at the cost of meaningful sexual side effect rates (4-7% in published trials). Mesotherapy delivery sacrifices some absolute efficacy for a dramatically improved safety profile — making it especially suitable for patients who are concerned about or have previously experienced sexual side effects from oral DHT blockers.
Treatment Protocol Details
Important note: Dutasteride mesotherapy is a clinical procedure that must be performed by a qualified dermatologist. The 0.01% concentration used in this study is specifically formulated for intradermal delivery and is not the same as oral dutasteride preparations. Never attempt to self-administer dutasteride injections.
Research Limitations to Consider
What This Means For Your Hair
This real-world study provides important context for anyone considering their hair loss treatment options. Here's what it means in practical terms:
Key Terms Explained
Frequently Asked Questions
Why is 0 sexual side effects in 541 patients such a big deal?
Oral dutasteride (0.5mg daily) carries a sexual side effect rate of approximately 4-7% in clinical trials. These effects — including reduced libido, erectile dysfunction, and ejaculatory changes — are the primary reason many patients refuse or discontinue oral DHT-blocking therapy. Finding zero cases across 541 patients treated with intradermal delivery suggests that mesotherapy fundamentally changes the drug's side effect profile by keeping it local rather than systemic. This is corroborated by the finding that serum hormone levels were unchanged after treatment. For the millions of people reluctant to take oral dutasteride due to side effect concerns, this represents a potentially important alternative delivery route.
Is 38.4% marked improvement a good result?
In context, yes. First, this figure represents "marked" improvement specifically — the highest category. Additional patients showed moderate improvement, meaning the total responder rate was higher than 38.4%. Second, this was assessed in a real-world setting with unselected patients, where results are typically lower than in optimised clinical trials. Third, these were monotherapy patients — the results might be even better when combined with other treatments (as most of the 541 patients were doing). For comparison, topical minoxidil 2% typically achieves visible improvement in 30-40% of women, and this study's monotherapy improvement rate is competitive with that benchmark.
Why did only 86 out of 541 patients get assessed for efficacy?
This is actually good scientific practice, not a limitation. Most patients receiving mesotherapy in real clinical practice also use other treatments — oral medications, topical minoxidil, PRP, etc. If a patient improves while using four treatments simultaneously, you can't determine which one is responsible. By restricting the efficacy analysis to the 86 patients who used mesotherapy as their only treatment, the researchers could be more confident that any improvement was due to the mesotherapy itself. The safety analysis, by contrast, used all 541 patients — because adverse events are attributable regardless of concurrent treatments.
How does dutasteride mesotherapy compare with minoxidil?
These treatments work through completely different mechanisms and are not direct competitors — they're complementary. Dutasteride blocks DHT production, addressing the hormonal driver of follicle miniaturisation. Minoxidil is a vasodilator and potassium channel opener that stimulates hair growth independently of hormonal pathways. Many clinicians use them together for maximum benefit. This study focused on mesotherapy delivery of dutasteride, but the enhanced-delivery principle applies to topical treatments too — which is where microneedling comes in.
Can I get dutasteride mesotherapy at a clinic near me?
Dutasteride mesotherapy is offered by some dermatology clinics and trichology centres, particularly in Europe, the Middle East, and parts of Asia. Availability varies by country and is influenced by local medical regulations. In some jurisdictions, dutasteride mesotherapy is considered an off-label use. When seeking treatment, ask about the specific concentration used (this study used 0.01%), the injection technique, session frequency, and whether the practitioner has experience with this specific protocol. Prices typically range from $200–500 per session, with quarterly sessions recommended.
Does this study prove mesotherapy is better than oral dutasteride?
No — this study didn't directly compare mesotherapy delivery against oral delivery. The oral form likely achieves somewhat higher efficacy rates due to the higher systemic dose, but at the cost of meaningful sexual side effect risks. What this study demonstrates is that mesotherapy provides meaningful clinical improvement with a dramatically better safety profile. Whether the trade-off of slightly lower efficacy for much better safety is worthwhile depends on the individual patient's priorities. For many patients — particularly those who have declined oral therapy due to side effect concerns — mesotherapy offers a middle ground that may not have existed before.
How does mesotherapy delivery relate to at-home microneedling?
Both mesotherapy and microneedling are based on the principle that getting past the skin barrier dramatically improves treatment delivery to hair follicles. Mesotherapy achieves this through professional intradermal injections with active drug solutions. Microneedling creates temporary micro-channels that allow topically applied products to penetrate much more deeply than they would through intact skin. While microneedling doesn't achieve the same depth or precision of drug delivery as mesotherapy, it shares the core principle and is accessible for home use. The Hairgenetix system combines microneedling with copper peptide serum — an evidence-based active ingredient — to leverage this enhanced-delivery mechanism at home.
Why were serum hormone levels unchanged despite using a DHT blocker?
This is the key finding that explains the safety profile. When dutasteride is taken orally at 0.5mg, it reaches the bloodstream and blocks 5-alpha reductase throughout the body, reducing serum DHT by approximately 90%. This systemic effect is responsible for the drug's sexual side effects. In this study, intradermal injection of just 1 mL of 0.01% dutasteride (a total dose of 0.1mg, delivered locally) achieved sufficient concentrations at the hair follicle level while being too dilute to meaningfully affect systemic hormone levels. The drug stayed where it was needed — in the scalp — rather than circulating throughout the body.
Original Study Citation
Saceda-Corralo, D., Moustafa, F., Moreno-Arrones, Ó., Jaén-Olasolo, P., Vañó-Galván, S., & Camacho, F. (2022). Mesotherapy with dutasteride for androgenetic alopecia: A retrospective study in real clinical practice. Journal of Drugs in Dermatology, 21(7), 742–747. https://doi.org/10.36849/JDD.6610
How to Cite This Summary
APA: Hairgenetix. (2025). Mesotherapy for hair loss: Real-world results from 541 patients — Plain-language study summary. Hairgenetix Research Library. https://hairgenetix.com/blogs/articles/mesotherapy-hair-loss-real-world-541-patients-2022
Informal: A 2022 multicentre retrospective study of 541 patients found that dutasteride mesotherapy produced marked improvement in 38.4% of monotherapy patients with zero serious or sexual adverse events (Saceda-Corralo et al., 2022). Summarised by Hairgenetix at hairgenetix.com.
Related Research on Hairgenetix
Enhanced Delivery: The Principle Behind Hairgenetix
This study demonstrates that delivering active ingredients directly to hair follicles — bypassing the skin barrier — produces meaningful results with an excellent safety profile. Whether through clinical mesotherapy injections or at-home microneedling, the principle is the same: enhanced delivery works.
The Hairgenetix system brings this principle home. Our medical-grade derma roller creates micro-channels that dramatically increase the absorption of our copper peptide serum — a scientifically studied active ingredient — directly into the scalp where follicles need it most.
Browse the Hairgenetix Collection →